Hormone-refractory prostate cancer
Not yet recruitingRandomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer
Randomized phase III study of AAA817 plus an androgen receptor pathway inhibitor in adult men with PSMA‑positive metastatic castration‑resistant prostate cancer
- Disease:Hormone-refractory prostate cancer
- Substances:AbirateroneBicalutamide+12
Slovakia- Participants:18–64 years · 65+ years
- Substances:Abiraterone
- Sponsor:Novartis Pharma AG












